The Application Effect of Radiofrequency Ablation Combined with Pembrolizumab on Hepatocellular Carcinoma and the Influence of Tumor Markers,CAC1,and CCNB2 Levels
Objective:To investigate the effect of radiofrequency ablation combined with pabolizumab on hepatocellular carcinoma(HCC)and the effects of tumor markers,CAC1 and CCNB2 levels.Methods:Selected from 2020.1 to 2023.1 were 60 cases of patients with hepatocellular carcinoma(HCC),divided into observation group and control group,30 cases each.The control group was treated with radiofrequency ablation and conventional chemotherapy after operation.The observation group was treated with pabolizumab on the basis of the control group.Compare the two groups of relevant indicators.Results:ORR and DCR in observation group were significantly higher than those in control group(P＜0.05).Level of tumor markers in observation group were lower than the control group after treatment(P＜0.05);After treatment,the positive rates of CAC1 and CCNB2 in observation group were lower than those in control group(P＜0.05).There was no difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusions:Radiofrequency ablation combined with pembrolizumab is effective in the treatment of hepatocellular carcinoma,which can improve the objective response rate and disease control rate,and reduce the level of tumor markers.The excellent efficacy may be related to the regulation of CAC1 and CCNB2,and the combined treatment is safe.
NETL
NSTL
万方数据
